Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
BioTheranostics, a provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID molecular cancer classifier. CancerType ID predicts tumor type in patients with metastatic cancers.
Diagnostica Stago offers expertise through two free electronic resources to educate health care professionals about hemostasis and thrombosis. The Stago-EdVantage Web site and iHemOStasis app for the Apple iPad offer ways to increase hemostasis knowledge; understand clinical situations, therapies, and detection methods; and apply practical skills to patient care.
Illumina and Natera announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq 2500 sequencing system and associated consumables for performing Natera’s noninvasive prenatal test (NIPT) Panorama.
Audit MicroControls’ Linearity FD General Chemistry Beckman AU simulates human patient serum samples for determining linearity, calibration verification, and verification of reportable range for albumin, alkaline phosphatase, ALT, total amylase, AST, total bilirubin, direct bilirubin, BUN, calcium, chloride, cholesterol, CO2, creatine kinase, creatinine, gamma-GT, glucose, iron, lactate, LDH, lipase, magnesium, phosphorous, potassium, sodium, total protein, triglycerides, and uric acid. This five-level lyophilized product, packaged as 10 × 5 mL, has a shelf life of two years and open-vial stability of seven days when stored at 2°C to 8°C.
A new study, conducted by researchers at the John A. Burns School of Medicine, University of Hawaii, and published in the Journal of Microbiology, evaluated the InBios DENV Detect IgM capture ELISA for qualitative detection of IgM antibodies to dengue virus recombinant antigens. Well-characterized clinical serum samples collected from Hawaii, Vietnam, Niue, Singapore, and American Samoa were tested with the InBios ELISA in comparison with an in-house DENV IgM antibody capture (MAC) ELISA. The agreement, sensitivity, and specificity of the InBios assay were 94, 92, and 94 percent, respectively.
AdvanDx, a provider of molecular diagnostic tests for identifying pathogens that cause critical infections in hospitalized patients, announced the commercial launch of Gram-Negative QuickFISH BC, the third FDA-cleared test in its QuickFISH blood culture pathogen identification platform.
GeneDx announced the launch of a comprehensive suite of genetic tests for inherited cancer, including a 26-gene panel for breast and ovarian cancer that includes BRCA1 and BRCA2 and next-generation sequencing-based multi-gene panels for colorectal cancer, pancreatic cancer, and endometrial cancer.
Next-generation sequencing technologies have become faster and more efficient while library preparation remains a bottleneck. Laboratories require high-throughput, high-quality, stable, clinically relevant, and reproducible sample preparations. Solutions to these problems must not only solve time constraints but do so without the human errors associated with manual methods.
Myriad Genetics’ myRisk Hereditary Cancer is a multi-gene diagnostic test that provides increased sensitivity by analyzing 25 genes associated with eight major cancers, including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma.
Each test report will include a genetic test result, a clinical risk report, and a health care management tool based on professional society guidelines, providing clear and actionable information to improve patient care regardless of whether the patient receives a positive or negative test result.
Thermo Fisher Scientific’s Peltier-cooled incubators with solid-state Peltier cooling are for biological and genomics laboratory researchers engaged in fruit fly and biochemical oxygen demand research.
